Results 141 to 150 of about 6,598 (226)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis [PDF]

, 2023
Sara Orsini, Edoardo Marrani, Ilaria Pagnini, Giovanni Taccetti, Vito Terlizzi, Gabriele Simonini   +5 more
openalex   +1 more source

545: Real-world experience of tezacaftor/ivacaftor/elexacaftor at a UK adult CF center

, 2021
Deval Gor, Thomas Simon FitzMaurice, D Nazareth, M. Walshaw   +3 more
openalex   +1 more source

Modulation of host inflammatory pathways by Pseudomonas aeruginosa extracellular vesicles in cystic fibrosis: impact of pulmonary exacerbation and elexacaftor-tezacaftor-ivacaftor treatment [PDF]

Marianna Said, Aszia Burrell, Brennan Harmon, Kylie I. Krohmaly, Marina Mazur, George M. Solomon, A. Hahn   +6 more
openalex   +1 more source

565: Significant reduction in abdominal symptoms assessed with CFAbd score over 4 weeks of treatment with elexacaftor/tezacaftor/ivacaftor—First results from the RECOVER study

, 2021
J. Mainz, Jane C. Davies, A. Fleming, B. Elnazir, M. Williamson, E. McKone, D. Cox, Barry Linnane, Carlos Zagoya, Paul McNally   +9 more
openalex   +1 more source

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment [PDF]

, 2022
Lakshmi Viswanathan, Eric Bachman, Simon Tian, Neil Ahluwalia, Yaohua Zhang, Harold S. Bernstein, Paul Panorchan   +6 more
openalex   +1 more source

443 Elexacaftor/tezacaftor/ivacaftor treatment promotes inflammation resolution in people with cystic fibrosis

, 2022
N. Robinson, G. Hardisty, J. Gillan, R. Gray   +3 more
openalex   +1 more source

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis [PDF]

, 2023
L.R. Caley, Heledd Jarosz-Griffiths, Lesley Smith, L. Gale, Joanne Barrett, L. Kinsey, Valerie A. Davey, M. Nash, Andrew Jones, J.L. Whitehouse, D. Shimmin, R. Andres Floto, H. White, D. Peckham   +13 more
openalex   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abs. Eradication in a Child with Cystic Fibrosis [PDF]

Marcela Kreslová, Josef Sýkora, Veronika Skalická, Hana Hrdinová, Jana Amlerová, Romana Kaslová, Jan Baxa, Veronika Schwarzová, Václav Koucký   +8 more
openalex   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

624 Elexacaftor/tezacaftor/ivacaftor for treatment of cystic fibrosis: Experience in Argentina from October 2021 to March 2022

, 2022
M. Martin, A. Mendez, M. Brown, M. Dziubecki, C. Damnotti, S. Basualdo, M. Nessi, C. Incardona   +7 more
openalex   +1 more source